Pharmaceutical giant Pfizer PFE1.28%increase; green up pointing triangle and French vaccine maker Valneva VLA 0.29%increase; green up pointing triangle reported positive topline results from their ...

Add Yahoo as a preferred source to see more of our stories on Google. A logo of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction — two ...

Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...